1 **Review Protocol**

2 Oral ulcers of COVID-19 patients: a scoping review protocol

3 **Author(s)**

4 Abanoub RIAD,^{1,2,†} Julien ISSA,^{3,†} Veronika CHUCHMOVA,² Simona SLEZAKOVA,¹ Esraa GOMAA,⁴
5 Andrea POKORNA,^{1,5} Jitka KLUGAROVA,^{1,2} Miloslav KLUGAR^{1,2}

6 **Affiliation(s)**

7 ¹ Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech
8 Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Institute of
9 Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic

10 ² Department of Public Health, Faculty of Medicine, Masaryk University, Brno, Czech Republic

11 ³ Department of Esthetic and Restorative Dentistry, Faculty of Dentistry, Saint Joseph University,
12 Beirut, Lebanon

13 ⁴ Department of Oral Medicine and Oral Radiology, Faculty of Dentistry, Egyptian Russian University,
14 Cairo, Egypt

15 ⁵ Department of Nursing and Midwifery, Faculty of Medicine, Masaryk University, Brno, Czech
16 Republic

17 **Corresponding Author**

18 Dr. Abanoub RIAD, DDS

19 **P.O.:** Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane
20 Czech Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Institute
21 of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno,
22 Czech Republic

23 **Email:** abanoub.riad@med.muni.cz

24 [†] These authors contributed equally to the work.

25 Abstract

26 **Objective:** This scoping review aims to systematically identify the types, characteristics, and possible
27 pathophysiologic etiologies of the oral ulcers that emerge in COVID-19 patients.

28 **Introduction:** The oral cavity is a vulnerable niche for the most diverse microbial ecosystem in the
29 human body; therefore, it presents a wide array of mucocutaneous complications that could indicate
30 various acute and chronic conditions. The COVID-19-related oral conditions, including oral ulcers,
31 had been widely debated as direct manifestations or indirect complications of the SARS-CoV-2
32 infection. According to a preliminary search of PROSPERO, MEDLINE, the Cochrane Database of
33 Systematic Reviews and the *JB I Evidence Synthesis*, there is no published nor registered scoping
34 review concerned with the oral ulcers of COVID-19 patients.

35 **Inclusion criteria:** The review will include studies included COVID-19 patients whose infection had
36 been confirmed by RT-PCR testing regardless of infection severity and clinical course. Only the
37 studies that reported COVID-19 patients with oral ulcers.

38 **Methods:** A three-phase search strategy will be carried out: an initial limited search, a full electronic
39 search, and hand search using the reference lists of all included records. The main bibliographic
40 databases of published literature will include MEDLINE® (Ovid), EMBASE (Elsevier), and Cochrane
41 COVID-19 Study Register. All identified records will be managed using EndNote 9.2, and the titles
42 and abstracts will be screened against the inclusion criteria before the full text of all potentially
43 relevant studies will be examined. The data will be presented in tabular form, rating maps, and
44 narrative summary.

45 **Registration:** This protocol had been pre-registered in Open Science Framework (OSF) Registries.^[1]

46 **Keywords:** Aphthous Stomatitis, COVID-19, Oral Manifestations, Oral Ulcer

47 **Abstract word count:** 244

48 **Total manuscript word count:** 1532

49 Introduction

50 The outbreak of the coronavirus disease (COVID-19) had required sensitive case definitions to be
 51 developed according to the dynamically growing epidemiologic evidence.^[2] The COVID-19-related
 52 extrapulmonary manifestations including the cutaneous lesions had been frequently reported since
 53 the beginning of this pandemic; however, it took several months until these lesions were recognized
 54 by the World Health Organization (WHO) within the clinical case definitions of COVID-19.^[2,3]
 55 According to the review of Daneshgaran *et al.* 2020, the vesicular rashes were suggested to be used
 56 for early diagnosis of COVID-19; while acral lesions were useful for epidemiological uses, and
 57 vascular rashes for the prognosis of the disease severity.^[4]

58 The oral cavity is subjected to numerous environmental factors that make it vulnerable to
 59 mucocutaneous complications. This vulnerability is supported by the fact that the oral cavity is a
 60 locus of the most diverse microbial ecosystem in the human body; therefore, it can harbour
 61 accessible lesions that could be diagnostic for an array of systemic conditions.^[5] Ulceration of the
 62 oral epithelium, underlying connective tissues, or both may last for two weeks or more, and it can be
 63 triggered by chronic conditions including drug-induced oral ulcers, lichen planus, pemphigus vulgaris,
 64 mucous membrane pemphigoid, lupus erythematosus, Reiter's syndrome, tuberculosis, eosinophilic
 65 ulcers, precancerous ulcers, and mycoses-related ulcers.^[6] Additionally, oral ulcers may be of acute
 66 nature and last for less than two weeks, e.g. traumatic ulcers, recurrent aphthous stomatitis (RAS),
 67 Bechet's disease, allergic reactions, erythema multiform, necrotizing sialometaplasia, hematologic
 68 disorders-related ulcers, and bacterial and viral infections. The clinical presentation of some viral
 69 infections like herpes simplex virus, varicella-zoster virus, coxsackievirus, cytomegalovirus,
 70 Epstein-Barr virus, measles virus, and human immunodeficiency virus (HIV) includes typically oral
 71 ulcers and vesicles which may aid in their timely diagnosis and management.^[7]

72 The oral symptoms of COVID-19 had been first reported in Lyon by Chaux-Bodard *et al.* 2020 as an
 73 irregular tongue ulcer which evolved concurrently with acral erythema preceding the COVID-19
 74 respiratory symptoms thus suggesting a promising epidemiological and clinical significance of the
 75 oral lesions as inaugural symptoms.^[8] In the following weeks, hundreds of individual cases with
 76 different oral lesions were reported in multiple countries to explain the nature and the aetiology of
 77 these lesions, which were equally distributed in females vs males.^[9-11] The COVID-19-related oral
 78 symptoms could be depicted as drug reactions, viral enanthem, stress-induced lesions, bacterial or
 79 fungal co-infections, or inflammatory reaction.^[9,11] Heretofore, the pathophysiological hypotheses of

COVID-19-related oral symptoms are supported by collateral observations that require further investigation; for instance, the hypothesis of viral enanthema is supported by the high expression of angiotensin-converting enzyme-2 (ACE-2) receptors in oral epithelium which serve as the primary entry of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); also the inflammatory response hypothesis is supported by the increasing number of cases of the pediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PMIS-TS).^[9,12] However, the onset of oral lesions had considerably varied across the reported cases due to lack of use of reference timepoints, it may indicate the variety of pathophysiologic etiologies and the natures of these lesions.^[9]

The COVID-19-related oral ulcers had been reported in critically-ill,^[13,14] moderate,^[15] mild^[15-17] and asymptomatic cases^[16]. Aphthous-like lesions were reported without necrosis and hemorrhagic crusts in younger patients, while in older patients with severe infection, the aphthous-like lesions had been necrotic and hemorrhagic.^[11] In a recent review of aphthous stomatitis in COVID-19 patients, the aphthous lesions were slightly predominant in females and people below 40 years old, and their onset ranged between 0 to 10 days since the emergence of the respiratory symptoms.^[15] The tongue was the most common location for ulcerative and erosive lesions of non-specific origin which appeared 3 days before the onset of respiratory symptoms in one of the cases.^[11] Herpetiform lesions were painful and emerged before, during, or after the respiratory symptoms.^[11]

This scoping review's primary objectives are to evaluate the breadth and depth of the evidence on oral lesions of COVID-19 patients and to evaluate their proposed pathophysiological courses and epidemiological and clinical significance. A preliminary search of PROSPERO, MEDLINE, the Cochrane Database of Systematic Reviews and the *JBI Evidence Synthesis* was conducted on January 20th, 2020, and no current or underway scoping reviews or systematic reviews on the topic were identified.

Review question(s)

What are the possible etiologies, types, and characteristics of the oral ulcers that emerge in COVID-19 patients?

Inclusion criteria

Participants

This review will consider studies that include COVID-19 patients whose infection had been confirmed

109 by means of RT-PCR.

110 *Concept*

111 This review will consider studies that reported any type of oral ulcers for example: solitary vs.
112 multiple, acute vs. recurrent, painful vs. painless, necrotic vs. non-necrotic, hemorrhagic vs.
113 non-hemorrhagic, or contagious vs. non-contagious.

114 *Context*

115 This review will consider studies that reported COVID-19 patients with mild, moderate, severe and
116 critic clinical courses according to the Australian guidelines for clinical care of COVID-19 patients.^[18]
117 The patients hospitalized either at intensive care or intermediate care (which provides more
118 intensive monitoring and patient management than the general ward but less than is offered in the
119 intensive care),^[19] and the patients who underwent home isolation will be included in this review.

120 *Types of sources*

121 This scoping review will consider descriptive as well as analytical epidemiological studies.
122 Furthermore, systematic reviews, narrative reviews and correspondence articles will be considered
123 for inclusion in the proposed scoping review.

124 **Methods**

125 The proposed scoping review will be conducted in accordance with the JBI methodology for scoping
126 reviews.^[20]

127 *Search strategy*

128 The search strategy will locate both published and unpublished primary studies, reviews, and
129 correspondence articles. A three-phase search strategy will be carried out. The first phase, which has
130 been already completed, was an initial limited search of MEDLINE® (Ovid) and Google Scholar to
131 identify relevant articles, followed by an analysis of the text words contained in the titles and
132 abstracts of retrieved records, in addition to the index terms used to describe these records. A full
133 search strategy for MEDLINE (PubMed) is stipulated in [Appendix 1](#). Secondly, the search strategy will
134 be developed according to the previous phase using all identified keywords and index terms, and it
135 will be customized for each included information source. Finally, the bibliographical reference lists of

all the included records will be screened for additional records.

Only studies published in English will be included. All the studies published since January 1st, 2020 will be included as the first cluster of COVID-19 cases was reported in Wuhan, China on December 30th, 2019.

Information sources

The databases to be searched include:

- MEDLINE® (Ovid)

- EMBASE (Elsevier)

- Cochrane COVID-19 Study Register

Study selection

Following the search, all identified records will be collated and uploaded into EndNote 9.2 (Clarivate Analytics, PA, USA) and duplicates removed. Following a pilot test, titles and abstracts will then be screened by two independent reviewers (A.R. and J.I.) against the inclusion criteria. The potentially relevant records will be retrieved in full and their citation details imported into the JBI System for the Unified Management, Assessment and Review of Information (JBI SUMARI; JBI, Adelaide, Australia).^[21] The full text of the selected records will be assessed in detail against the inclusion criteria by two independent reviewers (A.R. and J.I.). Reasons for exclusion of full-text records that do not meet the inclusion criteria will be recorded and reported in the scoping review. Any disagreements that arise between the reviewers at each stage of the selection process will be resolved through discussion or with a third reviewer (M.K.). The search results will be reported in full in the final scoping review and presented in a Preferred Reporting Items for Systematic Reviews and Meta-analyses for Scoping Reviews (PRISMA-ScR) flow diagram.^[22]

Data extraction

Data will be extracted from records included in the scoping review by two independent reviewers (A.R. and J.I.) using a draft charting form developed by the reviewers. The team will trial the charting form to ensure that all relevant results are extracted, and the table will be revised and amended when required during the data charting process. Modifications will be detailed in the full scoping review. Any disagreements that arise between the reviewers will be resolved through discussion or

with a third reviewer. The primary studies' authors will be contacted to request missing or additional data, where required. The data extracted will include specific details such as author(s), year of publication, country (where the cases were reported), study design, study population (age and gender), medical history, COVID-19 symptoms, ulcer characteristics (color, size, number, location, onset, and duration) and treatment. A draft extraction tool is provided (see [Appendix 2](#)).

Data analysis and presentation

The extracted data will be presented in tabular form according to the objectives of this scoping review. Additionally, rating maps will be used to display the frequency of reported cases. The tabulated results will be accompanied by a narrative summary demonstrating how the results relate to the scoping review's objectives.

Ethical consideration

The ethical committee of Masaryk University – Faculty of Medicine has exempted this study from getting approval due to the fact that it uses open-access data.

Conflicts of interest

The authors declare no conflict of interest.

Funding statement

Masaryk University supported the work of A.R. and V.C. by the grants MUNI/A/1608/2020 and MUNI/IGA/1543/2020. The work of A.R., A.P. J.K. and M.K. was supported by the INTER-EXCELLENCE grant number LTC20031 – “Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic”.

Data availability statement

The data that support the findings of this study are openly available in Open Science Framework at <https://doi.org/10.17605/OSF.IO/JWAU4>

References

1. Riad A, Issa J, Chuchmova V, Gomaa E, Pokorna A, Klugarova J, et al. Oral ulcers of COVID-19 patients: a scoping review protocol [Internet]. Open Science Framework (OSF) Registeries. 2021 [cited 2021 Jan 22]. Available from: <https://osf.io/jwau4>

- 191 2. World Health Organization (WHO). Coronavirus disease (COVID-19) [Internet]. [cited 2021 Jan
192 20]. Available from:
193 <https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19>
- 194 3. Wollina U, Karadağ AS, Rowland-Payne C, Chiriac A, Lotti T. Cutaneous signs in COVID-19
195 patients: A review [Internet]. Vol. 33, Dermatologic Therapy. Blackwell Publishing Inc.; 2020
196 [cited 2021 Jan 20]. Available from: /pmc/articles/PMC7273098/?report=abstract
- 197 4. Daneshgaran G, Dubin DP, Gould DJ. Cutaneous Manifestations of COVID-19: An
198 Evidence-Based Review [Internet]. Vol. 21, American Journal of Clinical Dermatology. Adis;
199 2020 [cited 2021 Jan 20]. p. 627–39. Available from:
200 <https://doi.org/10.1007/s40257-020-00558-4>
- 201 5. Chi AC, Neville BW, Krayner JW, Gonsalves WC. Oral Manifestations of Systemic Disease
202 [Internet]. Vol. 82, American Family Physician. 2010 Dec [cited 2021 Jan 20]. Available from:
203 www.aafp.org/afpAmericanFamilyPhysician
- 204 6. Muñoz-Corcuera M, Esparza-Gómez G, González-Moles MA, Bascones-Martínez A. Oral
205 ulcers: clinical aspects. A tool for dermatologists. Part II. Chronic ulcers. Clin Exp Dermatol
206 [Internet]. 2009 Jun 1 [cited 2021 Jan 20];34(4):456–61. Available from:
207 <http://doi.wiley.com/10.1111/j.1365-2230.2009.03219.x>
- 208 7. Muñoz-Corcuera M, Esparza-Gómez G, González-Moles MA, Bascones-Martínez A. Oral
209 ulcers: clinical aspects. A tool for dermatologists. Part I. Acute ulcers. Clin Exp Dermatol
210 [Internet]. 2009 Apr 1 [cited 2021 Jan 20];34(3):289–94. Available from:
211 <http://doi.wiley.com/10.1111/j.1365-2230.2009.03220.x>
- 212 8. Chaux-Bodard AG, Deneuve S, Desoutter A. Oral manifestation of Covid-19 as an inaugural
213 symptom? [Internet]. Vol. 26, Journal of Oral Medicine and Oral Surgery. EDP Sciences; 2020
214 [cited 2020 Nov 25]. p. 18. Available from: <https://doi.org/10.1051/mbcb/2020011>
- 215 9. Riad A, Klugar M, Krsek M. COVID-19 Related Oral Manifestations, Early Disease Features?
216 Oral Dis [Internet]. 2020 Jun 30 [cited 2020 Jul 13];odi.13516. Available from:
217 <https://onlinelibrary.wiley.com/doi/abs/10.1111/odi.13516>
- 218 10. Eghbali Zarch R, Hosseinzadeh P. COVID-19 from the perspective of dentists: A case report
219 and brief review of more than 170 cases. Dermatol Ther [Internet]. 2021 Jan [cited 2021 Jan

- 21]; Available from: <https://onlinelibrary.wiley.com/doi/10.1111/dth.14717>
11. Iranmanesh B, Amiri R, Zartab H, Aflatoonian M. Oral manifestations of COVID-19 disease: A review article. *Dermatol Ther* [Internet]. 2020 Nov 25 [cited 2020 Dec 8];dth.14578. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/dth.14578>
12. Riad A, Boccuzzi M, Sagiroglu D, Klugar M, Krsek M. Pediatric multisystem inflammatory syndrome temporally associated with SARS-COV-2: Oral manifestations and implications. *Int J Paediatr Dent* [Internet]. 2020 Aug 21 [cited 2020 Aug 30];ipd.12694. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/ipd.12694>
13. Amorim dos Santos J, Normando AGC, Carvalho da Silva RL, De Paula RM, Cembranel AC, Santos-Silva AR, et al. Oral mucosal lesions in a COVID-19 patient: New signs or secondary manifestations? [Internet]. Vol. 97, *International Journal of Infectious Diseases*. Elsevier B.V.; 2020 [cited 2020 Dec 10]. p. 326–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/32526392/>
14. Brandão TB, Gueiros LA, Melo TS, Prado-Ribeiro AC, Nesrallah ACFA, Prado GVB, et al. Oral lesions in patients with SARS-CoV-2 infection: could the oral cavity be a target organ? *Oral Surg Oral Med Oral Pathol Oral Radiol* [Internet]. 2020 Aug 18 [cited 2020 Dec 12]; Available from: <https://pubmed.ncbi.nlm.nih.gov/32526392/>
15. Riad A, Kassem I, Stanek J, Badrah M, Klugarova J, Klugar M. Aphthous Stomatitis in COVID-19 Patients: Case-series and Literature Review. *Dermatol Ther* [Internet]. 2021 Jan 3 [cited 2021 Jan 3]; Available from: <https://onlinelibrary.wiley.com/doi/10.1111/dth.14735>
16. Riad A, Kassem I, Hockova B, Badrah M, Klugar M. Tongue ulcers associated with SARS-CoV-2 infection: A case series. *Oral Dis* [Internet]. 2020 Sep 25 [cited 2021 Jan 13];odi.13635. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/odi.13635>
17. Al-Khanati NM, Riad A, Sahloul ME, Klugar M. Aphthous-like stomatitis of COVID-19 patients. *Brazilian J Oral Sci* [Internet]. 2020 Nov 4 [cited 2020 Dec 4];19:e201354–e201354. Available from: <http://dx.doi.org/10.20396/bjos.v19i0.8661354>
18. NHMRC NH and MRC. Australian Guidelines for the clinical care of people with COVID-19 [Internet]. Australian Clinical Practice Guidelines. 2020 [cited 2020 Sep 17]. Available from: <https://www.clinicalguidelines.gov.au/register/australian-guidelines-clinical-care-people-covi>

- 249 d-19
- 250 19. Vincent JL, Rubenfeld GD. Does intermediate care improve patient outcomes or reduce costs?
- 251 Crit Care [Internet]. 2015 Mar 2 [cited 2021 Jan 23];19(1):89. Available from:
- 252 <http://ccforum.com/content/19/1/89>
- 253 20. Peters M, Godfrey C, McInerney P, Baldini Soares C, Khalil H, Parker D. JBI Manual for
- 254 Evidence Synthesis [Internet]. JBI Manual for Evidence Synthesis. JBI; 2020 [cited 2021 Jan
- 255 21]. Available from: <https://wiki.jbi.global/display/MANUAL>
- 256 21. Munn Z, Aromataris E, Tufanaru C, Stern C, Porritt K, Farrow J, et al. The development of
- 257 software to support multiple systematic review types: The Joanna Briggs Institute System for
- 258 the Unified Management, Assessment and Review of Information (JBI SUMARI). Int J Evid
- 259 Based Healthc [Internet]. 2019 Mar 1 [cited 2021 Jan 22];17(1):36–43. Available from:
- 260 <https://pubmed.ncbi.nlm.nih.gov/30239357/>
- 261 22. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for
- 262 scoping reviews (PRISMA-ScR): Checklist and explanation [Internet]. Vol. 169, Annals of
- 263 Internal Medicine. American College of Physicians; 2018 [cited 2021 Jan 22]. p. 467–73.
- 264 Available from: <https://pubmed.ncbi.nlm.nih.gov/30178033/>

Appendix I: Search strategy

MEDLINE (PubMed)

Search conducted on February 6th, 2021, from (01.01.2020) to present.

Search	Query	Field	Records retrieved
Limited to the date range from (01.01.2020) to present			
#1	COVID-19 OR SARS-CoV-2 OR 2019-nCoV OR severe acute respiratory syndrome OR coronavirus OR corona virus	All Fields	100,753
#2	Oral OR mouth OR stomatitis OR cheilitis OR tongue OR lingual OR lip OR lip* OR labial OR buccal OR perioral OR palate OR palat* OR pharynx OR pharyn* OR oropharyn* OR gingiva OR tonsil OR lingual OR saliva* OR face OR facial OR salivary	All Fields	109,532
#3	Ulcer* OR ulcer OR ulcerative OR aphthous OR aphthae OR herpes OR herpe* OR blister* OR blister OR erosion OR erosion* OR erosi* OR lesion OR lesion* OR vesicle OR vesicle* OR pressure ulcer OR injuries OR injury OR complication* OR complication OR manifestation OR manifestation* OR damage OR scare OR scare* OR sore OR sore* OR erythema multiforme OR lichen planus OR lichen* OR pemphigus OR pemphigoid OR erythem* OR varicella OR coxsackie OR cytomegalovirus OR Epstein–Barr	Title / Abstract	257,772
#4	#1 AND #2 AND #3		1,038

Appendix II: Data extraction instrument

Author, Date, Location	Number of patients	Gender	Age	Medical anamnesis	COVID-19 symptoms	COVID-19 treatment	Ulcer characteristics				Ulcer Treatment
							Location	Number / Size	Necrosis / Hemorrhage	Onset / Duration	